-
公开(公告)号：DE69324152T2
公开(公告)日：1999-10-28
申请号：DE69324152
申请日：1993-11-05
Applicant: ABBOTT LAB
Inventor： BASHA ANWER , BHATIA PRAMILA , BROOKS DEE , CRAIG RICHARD , RATAJCZYK JAMES , STEWART ANDREW
IPC: A61K31/17 , A61K31/38 , A61K31/381 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4433 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P25/00 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00 , C07C273/18 , C07C275/24 , C07C275/64 , C07D213/61 , C07D277/28 , C07D307/52 , C07D333/20 , C07D333/22 , C07D405/06 , C07D409/04 , C07D409/06 , C07D417/04 , C07C275/20
Abstract: PCT No. PCT/US93/10675 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/11342 PCT Pub. Date May 26, 1994The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.
-
公开(公告)号：DE69324152D1
公开(公告)日：1999-04-29
申请号：DE69324152
申请日：1993-11-05
Applicant: ABBOTT LAB
Inventor： BASHA ANWER , BHATIA PRAMILA , BROOKS DEE , CRAIG RICHARD , RATAJCZYK JAMES , STEWART ANDREW
IPC: A61K31/17 , A61K31/38 , A61K31/381 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4433 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P25/00 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00 , C07C273/18 , C07C275/24 , C07C275/64 , C07D213/61 , C07D277/28 , C07D307/52 , C07D333/20 , C07D333/22 , C07D405/06 , C07D409/04 , C07D409/06 , C07D417/04 , C07C275/20
Abstract: PCT No. PCT/US93/10675 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/11342 PCT Pub. Date May 26, 1994The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.
-
公开(公告)号：AU8697698A
公开(公告)日：1999-03-16
申请号：AU8697698
申请日：1998-08-10
Applicant: ABBOTT LAB
Inventor： BLACK LAWRENCE A , BASHA ANWER , KOLASA TEODOZYJ , KORT MICHAEL E , LIU HUAQING , MCCARTY CATHERINE M , PATEL MEENA V , ROHDE JEFFREY J
IPC: C07D237/14 , A61K31/496 , A61K31/50 , A61K31/501 , A61K31/5377 , A61P5/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D20060101 , C07D237/10 , C07D237/16 , C07D237/18 , C07D237/20 , C07D237/22 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07F9/547 , C07F9/6509 , C07F11/00
Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号：CA2299300A1
公开(公告)日：1999-03-04
申请号：CA2299300
申请日：1998-08-10
Applicant: ABBOTT LAB
Inventor： MCCARTY CATHERINE M , PATEL MEENA V , KORT MICHAEL E , KOLASA TEODOZYJ , LIU HUAQING , ROHDE JEFFREY J , BASHA ANWER , BLACK LAWRENCE A
IPC: C07D237/14 , C07D237/18 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D409/06 , C07D409/12 , C07D417/06 , A61K31/50 , C07D413/06 , C07F11/00
Abstract: The present invention describes pyridazinone compounds which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX/2), COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
-
公开(公告)号：IE77040B1
公开(公告)日：1997-11-19
申请号：IE246991
申请日：1991-07-15
Applicant: ABBOTT LAB
Inventor： BROOKS DEE W , KERKMAN DANIEL J , BASHA ANWER , STEWART ANDREW O , BHATIA PRAMILA A , MARTIN JONATHAN G
IPC: A61K31/16 , A61K31/17 , A61K31/34 , A61K31/341 , A61K31/343 , A61K31/38 , A61K31/381 , A61K31/42 , A61K31/423 , A61K31/435 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/505 , A61P1/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P29/00 , A61P37/08 , C07C239/08 , C07C275/20 , C07C275/64 , C07C323/44 , C07C333/12 , C07D213/40 , C07D213/64 , C07D213/643 , C07D213/65 , C07D213/68 , C07D213/69 , C07D213/78 , C07D215/20 , C07D215/22 , C07D215/227 , C07D217/24 , C07D239/34 , C07D241/14 , C07D241/18 , C07D263/56 , C07D277/20 , C07D277/34 , C07D307/52 , C07D307/54 , C07D307/56 , C07D307/58 , C07D307/64 , C07D307/81 , C07D307/82 , C07D333/20 , C07D333/24 , C07D333/28 , C07D333/32 , C07D333/34 , C07D333/58 , C07D333/60 , C07D405/04 , C07D405/12 , C07D407/12 , C07D409/04 , C07D409/12 , C07C271/06 , C07C323/34
-
Patent Agency Ranking
公开(公告)号：GR3022120T3
公开(公告)日：1997-03-31
申请号：GR960403554
申请日：1996-12-20
Applicant: ABBOTT LAB
Inventor： BROOKS DEE W , STEWART ANDREW O , KERKMAN DANIEL J , BHATIA PRAMILA A , BASHA ANWER , MARTIN JONATHAN G
IPC: A61K31/16 , A61K31/17 , A61K31/34 , A61K31/341 , A61K31/343 , A61K31/38 , A61K31/381 , A61K31/42 , A61K31/423 , A61K31/435 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/505 , A61P1/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P29/00 , A61P37/08 , C07C239/08 , C07C275/20 , C07C275/64 , C07C323/44 , C07C333/12 , C07D213/40 , C07D213/64 , C07D213/643 , C07D213/65 , C07D213/68 , C07D213/69 , C07D213/78 , C07D215/20 , C07D215/22 , C07D215/227 , C07D217/24 , C07D239/34 , C07D241/14 , C07D241/18 , C07D263/56 , C07D277/20 , C07D277/34 , C07D307/52 , C07D307/54 , C07D307/56 , C07D307/58 , C07D307/64 , C07D307/81 , C07D307/82 , C07D333/20 , C07D333/24 , C07D333/28 , C07D333/32 , C07D333/34 , C07D333/58 , C07D333/60 , C07D405/04 , C07D405/12 , C07D407/12 , C07D409/04 , C07D409/12 , C07D333/36 , C07D307/66
-
公开(公告)号：PH30162A
公开(公告)日：1997-01-21
申请号：PH47213
申请日：1993-11-15
Applicant: ABBOTT LAB
Inventor： BROOKS DEE W , STEWART ANDREW O , BASHA ANWER , BHATIA PRAMILA , RATAJCZYK JAMES D
IPC: A61K31/17 , A61K31/38 , A61K31/381 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4433 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P25/00 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00 , C07C273/18 , C07C275/24 , C07C275/64 , C07D213/61 , C07D277/28 , C07D307/52 , C07D333/20 , C07D333/22 , C07D405/06 , C07D409/04 , C07D409/06 , C07D417/04 , C07D275/20
Abstract: PCT No. PCT/US93/10675 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/11342 PCT Pub. Date May 26, 1994The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.
-
128.发明专利
公开(公告)号：AU673040B2
公开(公告)日：1996-10-24
申请号：AU5666094
申请日：1993-11-05
Applicant: ABBOTT LAB
Inventor： BASHA ANWER , BHATIA PRAMILA , BROOKS DEE W , CRAIG RICHARD A , RATAJCZYK JAMES D , STEWART ANDREW O
IPC: A61K31/17 , A61K31/38 , A61K31/381 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4433 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P25/00 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00 , C07C273/18 , C07C275/24 , C07C275/64 , C07D213/61 , C07D277/28 , C07D307/52 , C07D333/20 , C07D333/22 , C07D405/06 , C07D409/04 , C07D409/06 , C07D417/04 , C07D333/28 , C07D417/06 , C07D333/56 , C07D333/54 , C07D409/12
Abstract: PCT No. PCT/US93/10675 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/11342 PCT Pub. Date May 26, 1994The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.
-
129.发明专利
公开(公告)号：AU5666094A
公开(公告)日：1994-06-08
申请号：AU5666094
申请日：1993-11-05
Applicant: ABBOTT LAB
Inventor： BASHA ANWER , BHATIA PRAMILA , BROOKS DEE W , CRAIG RICHARD A , RATAJCZYK JAMES D , STEWART ANDREW O
IPC: A61K31/17 , A61K31/38 , A61K31/381 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4433 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P25/00 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00 , C07C273/18 , C07C275/24 , C07C275/64 , C07D213/61 , C07D277/28 , C07D307/52 , C07D333/20 , C07D333/22 , C07D405/06 , C07D409/04 , C07D409/06 , C07D417/04 , C07C275/20
Abstract: PCT No. PCT/US93/10675 Sec. 371 Date Apr. 13, 1995 Sec. 102(e) Date Apr. 13, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/11342 PCT Pub. Date May 26, 1994The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.
-
公开(公告)号：CA2087836A1
公开(公告)日：1992-01-26
申请号：CA2087836
申请日：1991-07-11
Applicant: ABBOTT LAB
Inventor： BROOKS DEE W , STEWART ANDREW O , KERKMAN DANIEL J , BHATIA PRAMILA A , BASHA ANWER , MARTIN JONATHAN G
IPC: A61K31/16 , A61K31/17 , A61K31/34 , A61K31/341 , A61K31/343 , A61K31/38 , A61K31/381 , A61K31/42 , A61K31/423 , A61K31/435 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/505 , A61P1/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P29/00 , A61P37/08 , C07C239/08 , C07C275/20 , C07C275/64 , C07C323/44 , C07C333/12 , C07D213/40 , C07D213/64 , C07D213/643 , C07D213/65 , C07D213/68 , C07D213/69 , C07D213/78 , C07D215/20 , C07D215/22 , C07D215/227 , C07D217/24 , C07D239/34 , C07D241/14 , C07D241/18 , C07D263/56 , C07D277/20 , C07D277/34 , C07D307/52 , C07D307/54 , C07D307/56 , C07D307/58 , C07D307/64 , C07D307/81 , C07D307/82 , C07D333/20 , C07D333/24 , C07D333/28 , C07D333/32 , C07D333/34 , C07D333/58 , C07D333/60 , C07D405/04 , C07D405/12 , C07D407/12 , C07D409/04 , C07D409/12 , A61K31/33 , C07C323/47 , C07D263/58 , C07D333/30
Abstract: 2087836 9201682 PCTABS00010 Compounds of the structure (I) where p and q are zero or one, but cannot both be the same, M is a pharmaceutically acceptable cation or a metabolically cleavable group, B is a valence bond or a straight or branched alkylene group, R is alkyl, cycloalkyl or -NR1R2, where R1 and R2 are hydrogen, alkyl, cycloalkyl or alkanoyl, and A is optionally substituted carbocyclic aryl, furyl, benzol¢b!furyl, thienyl, or benzol¢b!thienyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.
-
-
-
-
-
-
-
-
-
Search Results
131
records
(took 0.023 seconds)
